- PR Newswire•3 days agoPropeller Health Completes $21.5 Million Financing to Transform Respiratory Disease through Digitally-Guided Therapy
MADISON, Wis., Oct. 20, 2016 /PRNewswire/ -- Propeller Health, the leading digital solution for respiratory medicine, today announced the closing of its $21.5 million Series C financing. The funding round includes new investors 3M Ventures, S.R. One, Limited and Hikma Ventures, and existing investors Safeguard Scientifics and Social Capital. Proceeds will be used to expand Propeller's digitally-guided therapy platform and modernize the management of respiratory disease.
- MarketWatch•20 days ago
The U.K. government sets a target by when it wants Brexit talks to begin, pushing equities higher while the pound suffers.
- Capital Cube•24 days ago
Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to Hikma Pharmaceuticals Plc Here are 5 ETF’s with the largest exposure to HIK-GB. Comparing the performance and risk of Hikma Pharmaceuticals Plc with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Hikma Pharmaceuticals PLC (HIK.L)
LSE - LSE Delayed Price. Currency in GBp
|Bid||1,800.00 x 16300|
|Ask||2,200.00 x 34600|
|Day's Range||1,905.00 - 1,971.00|
|52wk Range||1,575.00 - 2,703.00|
|1y Target Est||N/A|
|P/E Ratio (ttm)||23.31|
|Avg Vol (3m)||570,842|
|Dividend & Yield||N/A (N/A)|